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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20–50 %
90-day mortality. The limitations of vancomycin, the current standard therapy for MRSA, make treatment difficult.
The only other approved drug for treatment of MRSA bacteraemia, daptomycin, has not been shown to be superior to
vancomycin. Surprisingly, there has been consistent in-vitro and in-vivo laboratory data demonstrating synergy between
vancomycin or daptomycin and an anti-staphylococcal β-lactam antibiotic. There is also growing clinical data to support
such combinations, including a recent pilot randomised controlled trial (RCT) that demonstrated a trend towards
a reduction in the duration of bacteraemia in patients treated with vancomycin plus flucloxacillin compared to
vancomycin alone. Our aim is to determine whether the addition of an anti-staphylococcal penicillin to standard
therapy results in improved clinical outcomes in MRSA bacteraemia.
Methods/Design: We will perform an open-label, parallel-group, randomised (1:1) controlled trial at 29 sites in
Australia, New Zealand, Singapore, and Israel. Adults (aged 18 years or older) with MRSA grown from at least one
blood culture and able to be randomised within 72 hours of the index blood culture collection will be eligible for
inclusion. Participants will be randomised to vancomycin or daptomycin (standard therapy) given intravenously or
to standard therapy plus 7 days of an anti-staphylococcal β-lactam (flucloxacillin, cloxacillin, or cefazolin). The primary
endpoint will be a composite outcome at 90 days of (1) all-cause mortality, (2) persistent bacteraemia at day 5 or beyond,
(3) microbiological relapse, or (4) microbiological treatment failure. The recruitment target of 440 patients is based on an
expected failure rate for the primary outcome of 30 % in the control arm and the ability to detect a clinically meaningful
absolute decrease of 12.5 %, with a two-sided alpha of 0.05, a power of 80 %, and assuming 10 % of patients will not be
evaluable for the primary endpoint.
Discussion: Key potential advantages of adding anti-staphylococcal β-lactams to standard therapy for MRSA bacteraemia
include their safety profile, low cost, and wide availability.
Trial registration: ClinicalTrials.gov Identifier: NCT02365493. Registered 24 February 2015.
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Background
Staphylococcus aureus is one of the most important hu-
man bacterial pathogens, and causes a broad range of in-
fections, ranging from superficial skin infections, deep
skin and tissue abscesses and bone infections, to invasive
bloodstream infections [1]. Methicillin-resistant S. aureus
(MRSA) is resistant to the mainstay of S. aureus therapy,
the anti-staphylococcal penicillins (such as flucloxacillin)
and is hence more difficult to treat. Therapies for MRSA
are either less effective (e.g. vancomycin) or much more
expensive (e.g. daptomycin) than the anti-staphylococcal
penicillins are for methicillin-susceptible S. aureus. Alter-
native therapies, including novel combinations of existing
agents are, therefore, urgently required, particularly to
treat invasive MRSA infections, each episode of which re-
sults in a mortality of 20–50 % [2].
Invasive MRSA infection causes a substantial
burden of disease
The Australian and New Zealand Co-operative Outcomes
of Staphylococcal Sepsis (ANZCOSS) study included data
from 33 hospitals and found that of 10,085 Staphylococcus
aureus bacteraemia (SAB) cases in 6 years (2007–2012),
2881 (22 %) were MRSA with an average of 480 MRSA
bacteraemia (MRSA-B) cases per year [2]. Although data
are lacking, the disease burden is likely to be even higher
in large population centres in Asia as indicated by high
case numbers in hospitals in Singapore. Although hospital-
acquired MRSA infections have decreased in the US, UK
and Australia with improved infection control practices,
community-associated strains of MRSA have emerged in
the past 10–15 years and the majority of invasive MRSA
infections are now community-onset rather than noso-
comial [3]. This is reflected in ANZCOSS data, where
community-onset cases of MRSA-B (index blood cul-
ture taken earlier than 72 hours following admission)
increased from 51 % in 2007 to 69 % in 2012. Attempts
to prevent MRSA infections outside the hospital system
are unlikely to be effective, and further reductions in
the incidence of MRSA infections are not expected.
MRSA-B is associated with poor outcomes
Bloodstream infections with MRSA have a higher mortality
than those caused by methicillin-sensitive Staphylococcus
aureus (MSSA) [4]. The ANZCOSS dataset demonstrates
that 30-day mortality is higher at 24 % for MRSA com-
pared to 17 % for MSSA (P <0.001). In a Thai hospital,
mortality rates were 67 % and 46 % for MRSA and MSSA
respectively [5]. This high mortality, not only in Australia,
Singapore, New Zealand and Israel, but also in resource-
limited settings where SAB is common and infection
control practices are suboptimal, is a key reason for the
currently described randomised controlled trial (RCT).
Current therapies for MRSA-B are limited and associated
with poor outcomes
A significant factor contributing to poorer outcomes with
MRSA-B compared to methicillin-susceptible S. aureus
bacteraemia (MSSA-B) is the limitations of vancomycin
(the current standard antibiotic therapy for invasive MRSA
infections). Compared with anti-staphylococcal β-lactams
such as oxacillin and its derivatives (flucloxacillin, cloxacil-
lin, and nafcillin), vancomycin demonstrates slower bacter-
ial killing [6], poorer tissue penetration [7], slower clearance
of bacteraemia [8, 9] and higher mortality [10, 11]. For
MSSA bacteraemia in ANZCOSS, 30-day mortality was
21 % (133/638) and 12 % (937/6950) for those treated
with vancomycin or β-lactams respectively. Furthermore,
treatment with vancomycin compared to β-lactams was a
risk factor for 30-day mortality among all participants
with SAB, independent of MRSA versus MSSA status
(P <0.001) [2]. In addition, strains of MRSA with decreased
susceptibility to vancomycin (heterogeneous vancomycin
intermediate resistance S. aureus (hVISA)) are beginning
to emerge worldwide [12]. In recent years, several alterna-
tive agents to vancomycin have become available for the
treatment of MRSA-B, including linezolid, daptomycin
and ceftaroline. Each of these has been found to be non-
inferior to vancomycin for MRSA infections, but none
have been shown to be superior [13] and all are associated
with a high cost and a substantial risk of adverse effects
[14]. Thus vancomycin continues to be recommended as
the first-line agent for severe MRSA infections by both the
Infectious Diseases Society of America [15] and the
Australian Therapeutic Guidelines: Antibiotic [16]. Cef-
taroline has only recently become available for MRSA
pneumonia and skin infections, but no trials have yet
been completed comparing it with vancomycin for
MRSA-B. However, even if ceftaroline were to eventu-
ally prove more effective, its cost far exceeds that of
vancomycin (estimated drug cost for a 4-week course
of ceftaroline = A$8680, compared with vancomycin =
A$260). Ceftaroline resistance is an additional concern
with a recent Australian study finding overall resistance
rates of 17 % amongst MRSA and 41 % in sequence
type 239 MRSA [17].
An alternative strategy to improve outcomes from
MRSA-B is to combine vancomycin with a second agent,
aiming for synergistic bacterial killing [18, 19]. Neither li-
nezolid nor daptomycin demonstrate synergy with vanco-
mycin against MRSA [19]. However, β-lactam antibiotics,
to which MRSA is inherently resistant, demonstrate an
unexpected but consistent synergy with vancomycin and
daptomycin respectively against MRSA. Given that β-
lactams are cheap (e.g. 7 days of flucloxacillin costs $A47),
safe and widely available, they are an attractive alternative
to more expensive drugs as second agents to combine
with vancomycin.
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Previous studies of β-lactam combination therapy
Due to poor outcomes with vancomycin monotherapy,
and the emerging problem of decreased vancomycin sus-
ceptibility in MRSA [20], multiple research teams have
investigated the combination of vancomycin or dapto-
mycin with various β-lactam antibiotics (reviewed in de-
tail in Davis et al. [21]).
At least 16 in-vitro studies have explored synergy be-
tween vancomycin and β-lactams against MRSA isolates
[22–37], all but one of which found evidence of synergy
in some or all of the tested strains. These studies varied
in their methodology (checkerboard synergy testing or
time-kill curves), types of strains tested (MRSA versus
hVISA versus vancomycin intermediate Staphylococcus
aureus (VISA)) and the β-lactams used, but a consistent
finding across nearly all the studies was synergistic bac-
terial killing in most but not all strains tested. There was
a general tendency across these studies (and within some
studies [24, 34]) to an increasing degree of synergy with
increasing vancomycin minimum inhibitory concentra-
tions (MICs). Synergy has been reported with all β-lactams
tested (including cefazolin), but the largest effect has been
observed with oxacillin and nafcillin. Flucloxacillin is also
considered in the same antibiotic class of ‘anti-staphylo-
coccal semi-synthetic penicillins’.
The few studies that have assessed combinations of
vancomycin with β-lactams in animal models have all
found evidence of synergy [24, 29, 33]. Climo found faster
sterilisation of infection with vancomycin plus nafcillin in
MRSA rabbit endocarditis and renal abscess models [24].
Ribes tested various combinations of linezolid, vanco-
mycin and imipenem in a murine peritonitis VISA model
using time-kill curves, and found faster bacterial killing
with vancomycin plus imipenem compared with vanco-
mycin alone, in both strains tested [29]. Finally, Fernandez
investigated the anti-MRSA cephalosporin ceftobiprole
against an MRSA and a VISA strain in a rat endocarditis
model. They found good activity of ceftobiprole against
both strains in terms of sterilising vegetations and pre-
venting mortality; the combination of vancomycin plus
ceftobiprole led to faster killing on time-kill curves, but
similar rates of mortality and of sterilisation of vegetations
compared with ceftobiprole alone [33].
There are few published data on β-lactam-based combin-
ation therapy for MRSA in humans. In a single-centre
retrospective cohort study, Dilworth and colleagues de-
scribed the outcomes of 50 participants with MRSA-B who
received combination therapy with vancomycin and at least
24 hours of β-lactam (at their clinicians’ discretion), and
compared them with 30 participants treated at the same
hospital, during the same time period with vancomycin
alone [35]. They found a higher rate of microbiological
eradication in the combination therapy group (96 % versus
80 %, P = 0.02), which persisted on a multivariate model
attempting to control for potential confounders (adjusted
odds ratio for achieving microbiological eradication in the
combination group = 11.24, P = 0.01).
In the only prospective clinical trial to date (CAMERA1),
Davis et al. [38] randomised 60 patients with MRSA-B to
standard therapy with vancomycin alone, or to combin-
ation therapy with vancomycin and flucloxacillin. The
study was conducted in seven centres in Australia and
was open-labelled in design. Patients receiving combin-
ation therapy cleared bacteraemia at a mean of 2 days
compared to 3 days with standard therapy (P = 0.06).
At least 10 in-vitro studies have examined the com-
bination of daptomycin with various β-lactams against
MRSA and VISA strains [39–49]. The findings of these
studies are remarkably similar to the vancomycin/β-lac-
tam synergy papers cited above: synergy for most but
not all strains tested, and an increasing degree of syn-
ergy with increasing MICs to both vancomycin and
daptomycin. No studies have found evidence of antag-
onism with this combination. A recently published ani-
mal study mirrored the findings of the in-vitro studies.
Garrigos used a rat tissue cage model of MRSA infection
to study the combination of daptomycin with cloxacillin,
and found superior cure rates with the combination than
with daptomycin alone [50].
As for the vancomycin/β-lactam combination, there are
no clinical trials of daptomycin with β-lactams either pub-
lished or in trials registries. However, limited observational
data suggest this combination may be effective, particularly
MRSA with poor response to daptomycin. In a case series
of seven participants with persistent MRSA-B for more
than 1 week despite high-dose daptomycin, all had their
bacteraemia cleared within 48 hours once naficillin or oxa-
cillin was added to their therapy [51]. In a second case
series of 22 participants with persistent MRSA-B despite
daptomycin for a median of 10 days, the addition of cef-
taroline led to clearance of bacteraemia in all cases, in a
median of 2 days [52].
A key question that emerges from these data is: what is
the mechanism of the observed synergy? The mechanisms
have not been entirely elucidated, but are becoming
clearer over time. Increasing vancomycin resistance in S.
aureus is paradoxically associated with decreasing MICs
to oxacillin, and this so-called ‘see-saw effect’ [36, 53] is at
least in part due to deletion of the MecA gene in some
strains of VISA and vancomycin-resistant Staphylococcus
aureus (VRSA) [54, 55], and possibly to other structural
changes in penicillin-binding proteins and cell wall thick-
ness. β-Lactams have been shown to enhance binding of
daptomycin to the bacterial cell wall [49]. Finally, Sakoulas
et al. recently reported novel data derived from an ex-vivo
study of human blood which adds another potential ad-
vantage for the use of β-lactams for MRSA – they lead to
increased activity of innate host defence peptides such as
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cathelicidin LL-37 [56], which in turn allow more efficient
bacterial killing.
Thus there is considerable in-vitro and in-vivo and
growing clinical evidence that the combination of
vancomycin or daptomycin with a β-lactam may be
more effective than vancomycin or daptomycin alone
for improving outcomes of this common and devastat-
ing infection.
Hypothesis
We hypothesise that the addition of β-lactams to
standard therapy in adults with MRSA-B will lead to
synergistic bacterial killing and hence faster clearance
of bacteria from the bloodstream and other infected
foci, thereby reducing the risk of disseminated infec-
tion and death.
Primary objective
To determine whether 7 days of intravenous β-lactam
given intravenously (IV) in combination with standard
therapy will lead to better 90-day complication-free sur-
vival, compared to standard therapy alone in adult par-
ticipants with MRSA bloodstream infection.
Methods/Design
Overview of trial design
CAMERA2 is an investigator-initiated, multi-centre,
parallel-group, open-label, RCT powered for superior-
ity, which compares combination antibiotic therapy
with standard antibiotic therapy in adults with MRSA-
B. Ethical approval has been obtained from all relevant
Human Research Ethics Committees (HRECs) and In-
stitutional Review Boards (see Appendix for details).
Study setting
We are planning to recruit from 23 Australian, 1 New
Zealand, 3 Singaporean and 2 Israeli acute care hospitals.
Other sites may be added during the course of the study.
Sites have been selected on the basis of (1) their incidence
of MRSA-B (at least 10 cases per year and ideally 20),
(2) the availability of an experienced and committed
site principal investigator (PI), and (3) the availability of
a suitably qualified research nurse or senior registrar to
assist with study-related activities.
Eligibility criteria
Participant inclusion criteria
1. Age 18 years or older
2. At least one set of blood cultures positive for MRSA
3. Able to be randomised within 72 hours of blood
culture being collected
4. Likely to remain as an inpatient for 7 days following
randomisation
Participant exclusion criteria
1. Previous type 1 hypersensitivity reaction to β-
lactams
2. Mixed blood culture with more than one pathogen
(excluding contaminants – i.e. a mixed growth of
MRSA and coagulase-negative Staphylococcus (CNS)
is eligible, as long as the CNS is clinically judged to
be a likely contaminant)
3. Previous participation in the trial
4. Known pregnancy
5. Current β-lactam antibiotic therapy which cannot be
ceased or substituted
6. Patient’s primary clinician unwilling to enrol patient
7. Moribund (expected to die in next 48 hours with or
without treatment)
8. Treatment limitations that preclude the use of
antibiotics. Participants who are ‘not for
resuscitation’ or ‘not for ICU admission’ may still be
enrolled if they are for active management of
infection including the use of all necessary
antibiotics and intravenously administered fluids.
Interventions
Standard care arm
Either vancomycin given IV dosed in accordance with the
Australian Therapeutic Guidelines: Antibiotic version 15,
2014 [16] (15–20 mg/kg 12-hourly (q12h), preceded by a
loading dose of 20–35 mg/kg if considered appropriate by
the treating clinician) or the Infectious Diseases Society of
America (IDSA) guidelines [57] with subsequent adjust-
ment to maintain trough levels at 15–20 mg/dL or dapto-
mycin 6–10 mg/kg per day by intravenous infusion
(IVI) (both drugs will be adjusted for renal function,
see Tables 1, 2, 3, 4 and 5). Dosing of vancomycin may
follow local guidelines if broadly in line with the Australian
Therapeutic Guidelines: Antibiotic and the IDSA guide-
lines. The choice of vancomycin or daptomycin will be at
the clinician’s discretion. The non-antibiotic management
and duration of the intravenously administered vancomycin
or daptomycin will be at the clinicians’ discretion, but will
be in line with Australian Therapeutic Guidelines and IDSA
guidelines [15]. These recommend from 14 to 42 days of
intravenous treatment, depending on factors such as
the result of a blood culture at 2 to 4 days after index
blood culture, result of echocardiogram, and the pres-
ence and removal of a focus of infection.
Combination therapy arm
In addition to standard treatment, a β-lactam given IV will
be added for the first 7 calendar days following random-
isation (day 1 being the day of randomisation – hence pa-
tients will receive 6–7 days of β-lactam). This β-lactam
will be flucloxacillin 2 g q6h IVI in Australia and New
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Zealand, and cloxacillin 2 g q6h IVI in Singapore and
Israel (where flucloxacillin is not generally available). For
those with a history of minor allergy to any penicillin (rash
or unclear history, but not anaphylaxis or angioedema), it
will be cefazolin 2 g q8h IVI. For haemodialysis patients, it
will be cefazolin 2 g three times per week post dialysis.
Criteria for discontinuing or modifying allocated
interventions
Adjusting for renal function
The starting maintenance vancomycin dose will be guided
by Table 1.
For those on haemodialysis, blood is to be taken at the
commencement of each dialysis session and sent for an
urgent vancomycin level. The dose as per the nomogram
(Table 2) is then administered and timed for the vanco-
mycin infusion to be completed simultaneously with the
completion of dialysis.
Other antibiotic doses will be adjusted for renal func-
tion as per Table 3 ((flu)cloxacillin), Table 4 (cefazolin),
and Table 5 (daptomycin).
Change of ‘backbone drug’ (vancomycin or daptomycin)
after randomisation
Whilst unnecessary changes will be discouraged, it will be
left to the treating clinician’s discretion to switch these
drugs if needed. The most likely situation where a switch
might occur is if a patient is commenced on vancomycin,
but the vancomycin MIC of the MRSA isolate is later deter-
mined to be ≥1.5 μg/ml. If a patient develops a suspected
adverse drug reaction to daptomycin (e.g. raised serum cre-
atinine kinase (CK)) or vancomycin (e.g. rash), then clini-
cians may also choose to switch.
If a patient’s backbone drug is switched, they will still
be analysed in the group to which they were randomised
(standard or combination). In the subgroup analysis
(vancomycin vs daptomycin), they will be counted as the
drug which they received the majority of doses of in the
first 7 days post randomisation. For example, if a patient
switches from vancomycin to daptomycin on day 3, they
will be counted in the daptomycin group.
Switching to a backbone drug other than vanco-
mycin or daptomycin will be discouraged. If a partici-
pant is switched to another non-β-lactam backbone
drug (e.g. linezolid, cotrimoxazole, clindamycin, tigecyc-
line, quinupristin-dalfopristin) this will be a protocol devi-
ation, but they will continue on the study and will still be
analysed in the group to which they were randomised
(standard or combination). Switching the backbone drug
to ceftaroline (a β-lactam with anti-MRSA activity) at any
time in the first 90 days will be a protocol violation, but
the participant will remain in the study and be analysed in
the group to which they were randomised, but will be
excluded from the per-protocol analysis (in accordance
with criteria in section 2.10)
β-lactam use after randomisation
Standard therapy group: the use of all β-lactams will be
prohibited in participants allocated to the standard therapy
group for the first 14 days after randomisation, and will be
discouraged for the entire duration of intravenously admin-
istered vancomycin/daptomycin. If a patient develops an
indication for broadening of antibiotic therapy, the site PI
should recommend a non-β-lactam agent (e.g. clindamycin,
quinolones). If a patient allocated to the standard therapy
Table 1 Adjustment of starting maintenance vancomycin doses according to renal function (for a 70-kg adult)
Creatinine clearance (mL/min) Starting maintenance dosage Timing of trough (pre-dose) plasma concentration
measurement
More than 90 1.5 g 12-hourly Before the fourth dose
60 to 90 1 g 12-hourly Before the fourth dose
20 to less than 60 1 g 24-hourly Before the third dose
Less than 20 1 g 48-hourly 48 hours after the first dose
On haemodialysis [58] 25 mg/kg Immediately prior to next haemodialysis session
Table 2 Adjustment of ongoing vancomycin doses for those
on haemodialysis






Table 3 Adjustment of (flu)cloxacillin doses according to
renal function
GFR Flucloxacillin dose Cloxacillin dose
>50 ml/min 2 g q6h IVI 2 g q6h IVI
11–50 ml/min 2 g q6h IVI 2 g q6h IVI
≤10 but not on
haemodialysis
1 g q8h IVI 2 g q6h IVI
On continuous renal
replacement therapy
2 g q6h IVI 2 g q6h IVI
On haemodialysis Not for flucloxacillin
(cefazolin 2 g 3x/week)
Not for cloxacillin
(cefazolin 2 g 3x/week)
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group receives a β-lactam within the first 14 days post ran-
domisation in spite of this, this will be recorded as a proto-
col violation, but will remain in the study.
Combination therapy group: the β-lactam may be
switched (within the limits of flucloxacillin, cloxacillin
and cefazolin) by the patient’s clinician if there is a serious
clinical need to do so (e.g. suspected allergy or toxicity).
The β-lactam must be ceased at the end of day 7.
Strategies to improve adherence to protocol
Training of site principal investigators (PIs)
All site PIs will receive training with regards to the
study protocol and their reporting requirements by the
project manager, a study chief investigator (CI) or dele-
gate, prior to the site being opened for recruitment. All
site PIs will complete a computer-based training course
in Good Clinical Practice (GCP). The project manager
or delegate will have regular phone contact with all en-
rolling site investigators.
Checking of medication charts
The medication chart (be it paper or electronic) will be
checked regularly by the site PI or their delegate (registrar
or research nurse) for the first 14 days whilst an inpatient
to ensure adherence to the study protocol.
Outcomes
Primary outcome – complication-free 90-day survival
The primary outcome is a composite outcome measure
with four components, to be assessed 90 days after ran-
domisation (randomisation = day 1). These are any of:
1. All-cause mortality
2. Persistent bacteraemia at day 5 or beyond
3. Microbiological relapse – positive blood culture
for MRSA at least 72 hours after a preceding
negative culture
4. Microbiological treatment failure. Positive sterile site
culture for MRSA at least 14 days after
randomisation. This includes pus from deep tissue
or organ abscesses, synovial fluid, blood or other
normally sterile sites. It does not include urine,
sputum or superficial swabs
Secondary outcomes
All outcomes below refer to the time period from ran-
domisation to day 90:
1. All-cause mortality at days 14, 42 and 90 days
2. Persistent bacteraemia at day 2
3. Persistent bacteraemia at day 5 or beyond
4. Acute kidney injury defined as at least stage 1
modified RIFLE criteria (1.5-fold increase in the
serum creatinine, or glomerular filtration rate (GFR)
decrease by 25 %) at any time within the first 7 days,
or new need for renal replacement therapy at any
time from days 1 to 90. This endpoint does not
apply to participants who were already on
haemodialysis at randomisation
5. Microbiological relapse – positive blood culture
for MRSA at least 72 hours after a preceding
negative culture
6. Microbiological treatment failure. Positive sterile site
culture for MRSA at least 14 days after
randomisation
7. Duration of intravenously administered antibiotic
treatment
8. Direct healthcare costs
Rationale for these outcome measures
Primary outcome measure
Whilst the key outcome of interest is all-cause mortality, a
study powered to detect a clinically meaningful 5 % abso-
lute mortality reduction would require over 2000 partici-
pants, which is beyond the capacity of this study. Hence a
composite outcome measure incorporating mortality and
microbiological measures of treatment failure has been
chosen. Clinical assessments of treatment failure have been
avoided due to their subjective nature. Since there exists no
generally agreed upon outcome measure for SAB trials, we
generated the primary outcome measure according to the
following principles – we chose an outcome that was:
patient-centred and clinically meaningful; as objective as
possible; simple to measure with as small a departure as
possible from usual clinical processes; consensus from a
group of experts (the CIs) following repeated cycles of
Table 4 Adjustment of cefazolin doses according to renal
function
GFR Cefazolin dose
>40 ml/min 2 g q8h IVI
21–40 ml/min 1 g q8h IVI
≤20 but not on haemodialysis 1 g q12h IVI
On continuous renal replacement therapy 2 g q12h IVI
On haemodialysis 2 g 3x/week post dialysis
Table 5 Adjustment of daptomycin doses according to renal
function
GFR Daptomycin dose
>50 ml/min 6–10 mg/kg IVI q24h
11–50 ml/min 6–8 mg/kg q24h IVI
≤10 but not on haemodialysis 8 mg/kg q48h IVI
On continuous renal replacement therapy 8 mg/kg q48h IVI
On haemodialysis 8 mg/kg q48h IVI,
dose after dialysis
GFR glomerular filtration rate, IVI intravenous infusion, q6/8/12h 6/8/12-hourly
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assessment, discussion and reassessment; consistent with
outcomes used in contemporary RCTs (e.g. the ARREST
trial of adjunctive rifampicin for SAB [58]).
The 90-day post-randomisation time point was chosen
because the majority of participants will have com-
pleted their initial course of orally- and intravenously-ad-
ministered antibiotic treatment by this time; using 28-
day mortality may miss an important proportion of
infection-related mortality and hence later time points
are increasingly used [58].
Secondary outcome measures
Each component of the composite primary outcome
measure has been included as a secondary outcome meas-
ure. In addition, we have included acute kidney injury (de-
fined according to the validated RIFLE criteria [59]). This
is because several small studies have raised the possibility
of vancomycin plus β-lactam combinations being nephro-
toxic [60, 61], although both the cited studies involved
piperacillin-tazobactam as the β-lactam.
Endpoint assessment
The composite primary endpoint will be assessed by a
blinded Endpoint Adjudication Committee. This com-
mittee will consist of three infectious diseases physi-
cians (IDPs), to be appointed by the Trial Management
Committee. This committee will be provided with an
extract of study data that does not contain patient iden-
tifiers, and does not contain any mention of treatment
allocation or any detail about antibiotic treatment, but
does contain:
1. Demographic details (such as age and sex)
2. Comorbidities
3. Clinical details (including focus of infection, Sepsis-
related Organ Failure Assessment (SOFA) scores,
and echocardiography results)
4. Date and result of all blood cultures taken from the
index blood culture through to study day 90
5. Date and result of all other available clinical cultures
taken from days 1–90 (e.g. cultures of aspirated
pleural fluid or pus)
6. Vital status at day 90 and date of death if applicable
The members of the committee may request more in-
formation if needed, but this will only be provided if it is
available and does not provide direct or indirect evidence
of treatment allocation. Each of the three members of the
committee will then independently determine if, in their
view, the patient has met the primary endpoint. If there is
a discrepancy between the three assessments, the majority
will determine the endpoint.
Participant timeline
See Fig. 1 and Table 6 for a summary of participant
procedures.
Sample size
We have estimated that the failure rate for the primary out-
come in the control group will be 30 % (as per data from
the CAMERA1 study). We are aiming to detect a clinically
meaningful absolute reduction in failure by 12.5 %. The
absolute risk reduction we want to detect is based on what
is considered clinically significant – which is a subjective
quantity, based on expert opinion. When CIs of CAMERA2
were asked about this, the answers ranged from 10 to 15 %.
Hence we have arbitrarily taken the midpoint of 12.5 %,
resulting in a sample size required of 438 (including 11.1 %
inflation for 10 % drop out). A trial of 394 participants with
complete data for the primary outcome will provide 83 %
power to detect a statistically significant difference at the
two-sided 5 % level. We will, therefore, aim to randomise
440 participants to allow for approximately 10 % drop out
and have at least 394 participants for analysis.
Assignment of interventions
Allocation
Participants will be randomised in a 1:1 ratio to the stand-
ard or combination treatment arms, using a web-based
interactive randomisation system, available 24 hours per
day, 7 days per week (Spiral Software, Wellington, New
Zealand). Randomisation will be stratified by site, and by
receipt of haemodialysis, and will be in permuted blocks
of variable block size.
Allocation concealment
The randomised sequence allocation will be stored on a
secure server, and will not be available to any investiga-
tors or member of study staff.
Implementation
A commercial provider of randomisation services (Spiral
Software, Wellington, New Zealand) will generate the al-
location sequence and store it on their secure servers.
Participants will be enrolled by site PIs or their delegates
(research nurse or co-investigator (Co-I)). The person
enrolling the patient will, following obtaining written in-
formed consent, obtain the treatment allocation by log-
ging onto the web-based database and will then assign
the allocated treatment to the patient.
Blinding
This will be an open-label study, but the Outcome Adju-
dication Committee assessing the primary outcomes will
be blinded to treatment allocation.
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Data management
Source data
Source documents are those where data are first re-
corded, and from which participants’ case report form
(CRF) data are obtained. These include but are not lim-
ited to hospital records both electronic and paper (which
will include medical history, previous and current medi-
cations, any relevant radiography test, blood test results,
haemodynamic parameters and medical correspondence)
and paper or electronic clinic records (which will include
vital status, recent medical history and relevant blood cul-
ture results). A further potential data source will be through
telephone conversations with the study participant, person
responsible or GP.
Storage and archiving of study documents (CRFs and
consent forms) will be the responsibility of the site PI and
these will remain at the site of recruitment. All study par-
ticipants will be allocated a unique number at time of
screening (screening number); this screening number will
be added to all the CRFs for that participant. The partici-
pants will also have their hospital record number (HRN)
recorded on the CRFs as this information will be required
to ensure the correct medical record is accessed during
medical record reviews.
Data recording and record keeping
Data for this study will be recorded via a secure, Electronic
Data Capture (EDC) web-based system. It will be tran-
scribed by the site PI or their delegate from the paper CRFs
onto the EDC. Data will be stored in a re-identifiable man-
ner in the database, using a unique screening number for
each patient. The database will contain validation ranges
for each variable to minimise the chance of data entry er-
rors. An audit trail will maintain a record of initial entries
and changes made; reasons for change; time and date of
entry; and user name of person who made the change.
Data queries will be raised by the project manager and
study monitor, and missing data or suspected errors
will be raised as data queries and resolved prior to data-
base lock and analysis. The database will contain in-line
capability so that these queries and answers are logged
as part of the audit trail.
Blood culture taken in adult with 
suspected infection  
Bottle flags positive with Gram 
positive cocci in clusters 
Identified as MRSA 
Age>=18; <72h from blood draw; no type 1 allergy 
enrolled; informed consent; meets all inclusion and 
no exclusion criteria 
Randomise 440 
patients 1:1 to 
Combination therapy group 
clinician-determined duration of 
Vancomycin OR Daptomycin  + 7 
lactam  
Standard  therapy group - 
clinician-determined duration of 
Vancomycin OR Daptomycin 
Follow-up: Progress check at days 2, 5 and 7, then weekly whilst in 
hospital. Final follow-up day 90 post randomisation 
Primary endpoint: Death, persistent bacteraemia, microbiological 




























































Fig. 1 Trial flowchart
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The Trial Steering Committee will be the custodians of
the final trial dataset. No-one outside the Trial Steering
Committee will be given access to the data without the
permission of the Trial Steering Committee. No identify-
ing data will be given to any third parties at any stage.
Following study close out and locking of the database, it




Data will be reported in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) guidelines for
reporting of randomised trials. Proportions will be com-
pared between treatment groups with Fisher’s exact or χ2
tests, and the absolute difference in proportions reported
with corresponding 95 % confidence intervals. All-cause
mortality will be presented in a Kaplan-Meier graph.
The primary analysis of both primary and secondary
endpoints will be according to modified intention-to-
treat principles (all participants with data available for
the endpoint will be analysed according to the treatment
allocation, regardless of what treatment they received).
A secondary per-protocol analysis of all endpoints will
be conducted. The per-protocol population is defined as
(1) for the combination group: received at least 75 % of β-
lactam doses, (2) for the standard treatment group: re-
ceived at least one defined daily dose of β-lactam, (3) has
available day-90 data. For example, a patient who was allo-
cated to flucloxacillin 2 g four times a day (QID) for 7 days
(28 doses in total), must receive at least 21 doses during
the first 7 days to be included in the per-protocol popula-
tion. A patient on haemodialysis three times per week who
is prescribed cefazolin 2 g post dialysis, must have received
at least three doses in the first 7 days (i.e. have missed no
doses if dialysed three times on days 1–7 or a maximum
of one dose if dialysed four times on days 1–7). We will
perform the following subgroup analyses:
1. Standard treatment was daptomycin versus
vancomycin. This is because it is possible that
daptomycin and vancomycin are not equivalent in
terms of the primary outcome. Even though at least
one previous RCT has directly compared them and
found daptomycin to be non-inferior to vancomycin,
there was a trend towards improved success with
daptomycin for the MRSA subgroup [62]. Similarly,
the synergistic effect of a β-lactam may differ de-
pending on the backbone drug
2. Vancomycin MIC of primary isolate ≥1.5 μg/ml, or
<1.5 μg/ml. Synergy between β-lactams and vanco-
mycin or daptomycin appears to be more pro-
nounced in isolates with higher vancomycin MICs.
Conversely, higher vancomycin MICs have been
associated with worse outcomes, including higher
mortality [63]. The difference between the
Table 6 Schedule of visits, data collection and follow-up































Ensure blood cultures are
ordered by treating clinicians
x x x (x)a (x)a (x)a (x)a
Ensure FBC, EUC, LFTs, CRP
and vancomycin levels are
ordered by treating clinicians
x x x As clinically indicated
Vancomycin or daptomycin
doses
x x x x x x x x x (x)b (x)b (x)b
Combination therapy group:
β-lactam doses
x x x x x x x
Clinical progress assessment x x x x Weekly whilst
in hospital
x
Vital status (alive) x x x x x x x
Additional data review x x x x x
CRP C-reactive protein, EUC electrolytes urea and creatinine, FBC full blood count, LFTs liver function tests
aIf blood cultures are still positive at day 5, they should be recollected on day 7 and then every 48 hours until negative.
If they are negative on day 5, they should be recollected only if there is any clinical suspicion of relapse (eg. recurrent fever)
bMinimum recommended duration of vancomycin or daptomycin is 14 days – clinicians may choose to give longer courses, typically up to 42 days
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combination therapy group and the standard therapy
group is likely to be larger (in the direction of bene-
fit) in those with a higher vancomycin MIC
3. Participants receiving intermittent chronic
haemodialysis compared with those who are not.
Haemodialysis participants may have worse outcomes
from MRSA-B than those not on haemodialysis, and
they will be receiving a different β-lactam regimen
than others (cefazolin three times per week rather
than (flu)cloxacillin four times daily). Hence the
benefit of combination therapy may be smaller in
those on haemodialysis
4. Those who received more than 24 hours of β-lactam
antibiotics within the 72 hours prior to randomisa-
tion compared with those who did not. The effect of
any intervention for MRSA-B is likely to be greatest
within the first 24–48 hours after onset. The benefit
of combination therapy is likely to be smaller in
those who have received β-lactams prior to random-
isation, because of a dilution of effect (the control
group having received the intervention for a time)
5. Uncomplicated versus complicated SAB
(uncomplicated SAB defined as per IDSA guidelines:
exclusion of endocarditis; no implanted prostheses;
follow-up blood cultures performed on specimens
obtained 2–4 days after the initial set that do not
grow MRSA; defervescence within 72 hours of initi-
ating effective therapy; and no evidence of metastatic
sites of infection) [15]. Complicated SAB partici-
pants have worse outcomes and longer durations of
bacteraemia. The effect of combination therapy is
likely to be larger in this group. Because we expect the
combination therapy arm to result in a shorter
duration of bacteraemia and thus fewer patients to
have positive blood cultures at days 2–4, we will also
use an a-priori definition of uncomplicated SAB that
does not include the blood culture criteria at days 2–4
6. Participants recruited in Australia/New Zealand
versus Singapore versus Israel. We expect that
approximately 50 % of patients will be recruited
from Singapore
7. Those with baseline immunosuppression versus those
without. These are different patient groups with
regards to underlying comorbidities and risk for
severe sepsis
8. Participants with endocarditis affecting the left
side of the heart versus those without. Those with
endocarditis affecting the left side of the heart
generally have a poorer prognosis than those
without endocarditis
9. Participants with community-associated MRSA
versus healthcare-associated MRSA (defined either
genotypically or by non-multi (nmMRSA) versus
multidrug-resistant (mMRSA) phenotype; nmMRSA
defined as resistant to fewer than three classes of
non-β-lactam antibiotics, and mMRSA as resistance
to at least three classes of non-β-lactam antibiotics).
A simple health economic analysis will also be carried
out, using the primary outcome measures for the trial to
inform a modelling study. We will make use of cost and
quality of life estimates from other studies/data sources.
Interim analyses and stopping guidelines
The Data Safety and Monitoring Board (DSMB) will
conduct an interim analysis after 220 patients have
been randomised and followed for 90 days, or 2 years
following the date of the first patient randomised,
whichever comes first.
The interim analysis will review outcome data and an-
swer the following questions:
1. Are there any significant safety issues that may
present an ethical issue in continuing the study?
This may include adverse events, but also study
conduct and protocol violations
2. Are there overwhelming data suggesting the
superiority of one arm that may present an ethical
issue in continuing the study?
(a) Using the Haybittle-Peto rule, and 90-day all-
cause mortality as the outcome of interest, the
study will be stopped early if there is a difference in
90-day mortality rate with a P value of less than or
equal to 0.001
3. Are there any other factors that may impact on the
feasibility/usefulness of the study? For example, rate
of enrolment, unexpected low rate of outcomes,
unable to fund, protocol violations, etc.
Monitoring and trial co-ordination
Trial co-ordination
This trial will be co-ordinated from the Menzies School of
Health Research in Darwin (CIs Davis, Tong and Chatfield,
and study co-ordinator #1), in collaboration with the
Singapore Infectious Diseases Clinical Research Net-
work (CI Lye and study co-ordinator #2). The study will
also have input from the Australasian Society for Infec-
tious Diseases (ASID) Clinical Research Network (CRN)
and the Australian Kidney Trials Network (AKTN).
Data Safety and Monitoring Board
An independent DSMB will be established to review the
progress of the study and monitor adherence to the
protocol, participant recruitment, outcomes, complica-
tions, and other issues related to participant safety. They
will also monitor the assumptions underlying sample
size calculations for the study and alert the investigators
if they see substantial departures as the data accumulate.
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The DSMB will be composed of experts in infectious
diseases, biostatistics and clinical trials. The DSMB
members will all be independent of the investigators
(none of them will be CIs or site investigators).
The DSMB will make recommendations as to whether
the study should continue or be terminated, consider
participant safety or other circumstances as grounds for
early termination, including either compelling internal
or external evidence of treatment differences or feasibil-
ity of addressing the study hypotheses (e.g. poor partici-
pant enrolment, poor adherence).
Study monitoring
Study monitoring will be provided by the responsible
monitor(s) at the Menzies School of Health Research (or
designee) in accordance with the Monitoring Plan and
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Hu-
man Use: Good Clinical Practice.
The responsible monitor will visit each study site at least
once per year and will be allowed, on request, to inspect
the various records (source documents, paper CRFs, elec-
tronic case report forms (eCRFs) and other pertinent data)
provided that subject confidentiality is maintained in ac-
cord with local requirements.
It will be the monitor’s responsibility to inspect the
eCRFs throughout the study, to verify the adherence to
the protocol and the completeness, consistency and ac-
curacy of the data being entered on them. The monitor
must verify that the subject received the study drug as
randomised. The monitor should have access to labora-
tory test reports and other subject records needed to
verify the entries on the eCRF. The site PIs agree to co-
operate with the monitor to ensure that any problems
detected in the course of these monitoring visits are re-
solved in a timely manner.
Safety
All trial medications are licensed for use in Australia,
Singapore, New Zealand, and Israel with established
safety profiles.
Serious adverse events (SAEs)
A SAE is defined as any experience that:
 Results in death
 Is life-threatening
○ The term ‘life-threatening’ refers to an event in
which the subject was at risk of death at the
time of the event. It does not refer to an event,
which hypothetically may have caused death,
if it were more serious
 Results in unexpected prolongation of existing
hospitalisation
 Results in persistent or significant disability/
incapacity
 Is a medically important event or reaction
In this trial, expedited reporting of SAEs to HREC will
only be required if they are thought by the reporting
clinician (the site PI or their delegate) to be related to
the intervention arm study drugs (possibly, probably or
definitely as defined above). Such SAEs will be reported
on the SAE Reporting Form by the site PI or delegate to
the sponsor or delegate within 24 hours of the site study
team becoming aware of it. The site PI will also report
the SAE to the lead HREC for their site within 72 hours.
If it is also an unexpected drug reaction, the sponsor or
delegate will report to the Therapeutic Goods Adminis-
tration (TGA).
Adverse drug reactions (ADRs)
Investigators will be asked to report all suspected ADRs
(regardless of severity or seriousness) which are thought to
be related to study drugs in both intervention and control
arms (including vancomycin, daptmoycin, flucloxacillin,
cloxacillin and cefazolin). These data will be collected
routinely on CRF5.
SUSARS (suspected unexpected serious adverse drug reactions)
ADRs which are serious (as defined for SAEs above) and
are unexpected (as defined by not being listed as an adverse
effect in the approved product information) and are related
to the intervention arm study drug (i.e. the β-lactam) will
qualify for expedited reporting to the sponsor. As for SAEs,
the site PI or their delegate will also report the SUSAR to
the HREC within 72 hours. In addition, the sponsor will re-
port the SUSAR to the TGA within 7 calendar days for fatal
and life-threatening unexpected serious ADRs, and within
15 calendar days for other serious ADRs.
Causality
The site PI will make a judgement regarding whether
an adverse event is clinically significant and whether
or not it is related to the allocated treatment. The de-
gree of certainty with which an adverse event is attrib-
utable to treatment or an alternative cause will be
determined by how well the event can be understood
in terms of:
 The temporal relationship with the administration of
the treatment or cessation of treatment
 Reactions of a similar nature previously observed in
the individual or others following treatment
The relationship of the adverse event to treatment will
be specified as follows:
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Not related In the PI’s opinion, there is not a causal
relationship
Unlikely The temporal association between treatment
and the adverse event is such that treatment is
not likely to have any reasonable association
Possibly The adverse event could have been caused by
treatment
Probably The adverse event follows a temporal se-
quence from the time of treatment and can-
not be reasonably explained by the known
characteristics of the subject’s clinical pres-
entation/history
Definitely The adverse event follows a reasonable tem-
poral sequence from the time of treatment
or reappears when the treatment is repeated
Non-expedited reporting of adverse events and adverse
drug reactions
In addition to the expedited reporting described above,
a summary of all ADRs (to any of the study drugs in-
cluding vancomycin, daptomycin or the beta-lactams),
including SAEs and SUSARs, will be provided to the HREC
and DSMB on a regular basis for review, with the fre-
quency determined by each HREC’s policy.
Ethical considerations
General ethical considerations
The study will be conducted according to the declar-
ation of Helsinki, the Australian National Health and
Medical Research Council (NHMRC) criteria for the
ethical conduct of research in humans and the princi-
ples of GCP [64].
All antimicrobials in this study are registered for use in
Australia, Singapore, New Zealand, and Israel. The inter-
vention (the addition of β-lactam to standard therapy) is
unlikely to cause harm, and has proven safe both in pub-
lished human studies and in our own pilot RCT. Further-
more, this combination is routinely used in participants
with SAB prior to the availability of antibiotic susceptibil-
ity results. MRSA-B is a common condition whose out-
comes remain unacceptable with current therapies and
this fact along with the strong in-vitro and in-vivo signals
justify the conduct of this RCT. Written informed consent
will be sought from all participants; in some jurisdictions,
consent will be sought from a surrogate decision-maker if
the patient is not competent to consent. Approval will be
sought from relevant HRECs for all sites. See Appendix
for details of approving ethics committees.
Informed consent
An informed consent discussions will be held with each
participant or, for those not competent to make their
own decisions (e.g. unconscious), their person respon-
sible. ‘Person responsible’ consent will only be used in
jurisdictions where it is allowed, and where the site has
research governance approval to do so. The consent
process will be carried out by a site investigator or their
suitably trained delegate. The information for the discus-
sion will be provided in written and oral formats that
have been approved by the HREC and in a language
comprehensible to the potential participant or their per-
son responsible, using interpreters if necessary. In the
event that a participant who was not competent when
initially recruited into the study becomes competent to
make their own decisions, the participant will have the
study explained to them and an opportunity to consent
to remaining in the study or to withdraw. The site inves-
tigator or delegate will regularly check to see if the par-
ticipant becomes competent.
The participant or person responsible will personally
sign and date the latest approved version of the consent
form, as will the site investigator or their delegate who
conducted the consent discussion. If one was used, an in-
terpreter will also sign and date the consent form. A copy
of the information statement and consent form will be
provided to the participant. No trial-related procedure will
be undertaken before documented informed consent is
obtained. An original copy of the consent form will be
retained at the recruitment site by the site investigator.
Dissemination policy
The trial results will be communicated to all site PIs
prior to publication or presentation. The trial results will
be presented at national and international scientific con-
ferences. The trial results will also be submitted for pub-
lication to a peer-reviewed scientific journal, irrespective
of the results. A plain-language summary of the trial re-
sults will be made available to individual participants
upon request. The decision where to publish will be
made by the Study Steering Committee. The authorship
of the paper will include all of the Study Steering Commit-
tee who meet International Committee of Medical Journal
Editors (ICJME) criteria for authorship. Contributions of
other study participants will be recognised by the following
language at the end of the named authors’ list: ‘. . . and the
CAMERA2 study group for the ASID Clinical Research
Network’. The CAMERA2 study group will consist of all
named site investigators, and will be listed in the collabo-
rators section of the paper.
Discussion
MRSA-B is common (over 2880 cases each year in
Australia, and 80,000 in the USA), and has an unacceptably
high mortality (20–30 %) despite modern supportive care.
Indeed, deaths from invasive MRSA infections now out-
number deaths from HIV in the United States [65]. Mortal-
ity rates are even higher (50 %) in resource-limited settings
[5]. For the past 20 years, researchers and clinicians have
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been searching for an alternative treatment to vancomycin
for MRSA-B [14]. Several new and expensive drugs have
been marketed for this indication, but none has proved su-
perior to vancomycin. β-Lactam combination antibiotic
therapy has the potential to improve outcomes from
MRSA-B, at a very small cost.
There is increasing interest internationally in the role
of β-lactam combination therapy for invasive MRSA in-
fections, but most research has thus far focussed primar-
ily on in-vitro laboratory work. This current study will
be the first RCT with key clinical endpoints to address
this important question, and hence the result (whether it
be positive or negative) will influence practice around
the world. We have designed the trial with generalisabil-
ity in mind; the results will apply to patients on haemo-
dialysis (in whom S. aureus infections are an important
problem, but are often excluded from such trials), pa-
tients in wealthy regions including the USA and Europe
where daptomycin is commonly used, and, potentially,
patients in resource-limited regions, who would be able
to afford vancomycin plus flucloxacillin.
Trial status
The CAMERA2 trial opened its first site for recruitment
on 24 August 2015 and randomised its first patient on
26 August 2015.
Appendix
Appendix for CAMERA2 – combination antibiotic
therapy for methicillin-resistant Staphylococcus aur-
eus infection: study protocol for a randomised con-
trolled trial.
Names of ethical review committees which have reviewed
and approved the CAMERA2 study:
1. Hunter New England Human Research Ethics
Committee. This covers all sites in New South Wales,
Queensland, Victoria and South Australia. Reference
number 15/02/18/3.05
2. Human Research Ethics Committee of the Menzies
School of Health Research and Northern Territory
Department of Health. This covers the Royal Darwin
Hospital site. Reference number HREC 2015-2339
3. Royal Perth Hospital Ethics Committee. Covers all
WA sites. Reference number REG 15-008
4. New Zealand Central Health and Disability Ethics
Committee. Covers all New Zealand sites. Reference
number 15/CEN/95
5. Singapore National Health Group Domain Specific
Review Board – Domain E. Covers Singapore sites.
Reference Number 2015/00508
6. Human Research Ethics Committee of Rambam
Health Corporation. Covers Rambam Hospital Israel.
Reference Number 0322-15-RMB
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